The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis

Abstract

Benign prostatic hyperplasia is a common non-malignant condition among older men, but the epidemiology is poorly characterised. We summarised and determined the global prevalence of benign prostatic hyperplasia. A systematic search on PubMed, EMBASE and CENTRAL was performed up until 31st July 2016. Studies that described the epidemiology of benign prostatic hyperplasia were included and cumulative plots of prevalence estimates were calculated. A total of 31 prevalence rate estimates from 25 countries were identified. The combined prevalence estimates showed that the lifetime prevalence of BPH was 26.2% (95% CI: 22.8–29.6%). We found that there was an increasing prevalence of BPH with age. However, we found no significant difference between (a) rural, urban or mixed sites, (b) different countries, (c) respondent representativeness. (d) sample size or (e) study quality. We also found no significant change in the prevalence over the past 20 years. While there is substantial variation between sites estimates, results suggest that nearly 1 in 4 men will suffer from BPH over their lifetime. The study revealed there are significant gaps in knowledge, which provides opportunities for future research to further enrich the epidemiological landscape with data.

Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe

“…Of 100 (17.4%) patients who reported TEAEs leading to permanent discontinuation of Patients who had Vesomni added to their original monotherapy with an α-blocker or 5-ARI. 2 Patients who were switched to Vesomni from their original monotherapy with an α-blocker or 5-ARI. 3 Patients who had Vesomni added to their original treatment with an α-blocker and 5-ARI monotherapy.…”

“…1 The global prevalence of LUTS has been estimated to range from 14.8% among men aged 40 to 49 years to 38.4% among men aged ≥ 80 years. 2 Notably, nearly half of the men with LUTS report both storage and voiding symptoms. 3 Although the underlying pathophysiology of LUTS has not been fully elucidated, changes in both prostate and bladder physiology have been implicated.…”

Health‐related quality of life in patients undergoing TURP: Translating evidence into urological nursing practice

“…2,3 The combined prevalence of BPH is approximately 26.2% at the world level. 4 It is also reported that BPH increases with age and affect more than 70% of elderly males. 5,6 In order to reduce the complexities of BPH, innovative treatments developed in clinical practice have been widely employed with various efficacy and safety profiles.…”

α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines

“…A meta-analysis on studies from 25 countries showed that the lifetime prevalence of BPH was 26.2% [95% confidence interval (CI): 22.8-29.6%] and there were no regional or ethnic differences (Lee et al, 2017). In addition, in the United States alone, the annual spending on BPH treatment is estimated to be approximately $4 billion (Taub and Wei, 2006).…”